BridgeBio Pharma Inc vs Icl Group Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Icl Group Ltd trades at $5.43 (market cap $6.94B). The key difference: BridgeBio Pharma Inc is far larger — about 2.4× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.86% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ICL | |
|---|---|---|
Market Cap | $16.36B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $6.84 |
52-Week Low | $47.29 | $4.80 |
Enterprise Value | $18.14B | $9.58B |
Dividend Yield | — | 3.86% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →